Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsi Talala

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
European Urology Open Science|May 28, 2026
Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)Marianne Månsson, Kirsi Talala, Anssi Auvinen, et al.
Social Psychiatry and Psychiatric Epidemiology|February 28, 2009
Trends in socio-economic differences in self-reported depression during the years 1979-2002 in FinlandKirsi Talala, Taina Huurre, Hillevi Aro, et al.
BJU International|January 22, 2025
Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy resultJuho Pylväläinen, Kirsi Talala, Jani Raitanen, et al.
European Journal of Epidemiology|June 29, 2006
25-year trends and socio-demographic differences in response rates: Finnish adult health behaviour surveyHanna Tolonen, Satu Helakorpi, Kirsi Talala, et al.
European Journal of Epidemiology|September 26, 2009
Marital status, educational level and household income explain part of the excess mortality of survey non-respondentsHanna Tolonen, Tiina Laatikainen, Satu Helakorpi, et al.
Scandinavian Journal of Urology|August 19, 2021
Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trialVeera Soronen, Kirsi Talala, Jani Raitanen, et al.
European Urology Focus|August 15, 2017
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer CentresLasse Saarimäki, Jonas Hugosson, Teuvo L Tammela, et al.
Plos One|April 22, 2016
Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening TrialThea Veitonmäki, Teemu J Murtola, Kirsi Talala, et al.
Cancer Causes & Control : CCC|July 27, 2021
Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate CancerS D Walter, Jiarui Hu, Kirsi Talala, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2018
Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register dataNeill Booth, Pekka Rissanen, Teuvo L J Tammela, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
European Urology Open Science|May 28, 2026
Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)Marianne Månsson, Kirsi Talala, Anssi Auvinen, et al.
Social Psychiatry and Psychiatric Epidemiology|February 28, 2009
Trends in socio-economic differences in self-reported depression during the years 1979-2002 in FinlandKirsi Talala, Taina Huurre, Hillevi Aro, et al.
BJU International|January 22, 2025
Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy resultJuho Pylväläinen, Kirsi Talala, Jani Raitanen, et al.
European Journal of Epidemiology|June 29, 2006
25-year trends and socio-demographic differences in response rates: Finnish adult health behaviour surveyHanna Tolonen, Satu Helakorpi, Kirsi Talala, et al.
European Journal of Epidemiology|September 26, 2009
Marital status, educational level and household income explain part of the excess mortality of survey non-respondentsHanna Tolonen, Tiina Laatikainen, Satu Helakorpi, et al.
Scandinavian Journal of Urology|August 19, 2021
Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trialVeera Soronen, Kirsi Talala, Jani Raitanen, et al.
European Urology Focus|August 15, 2017
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer CentresLasse Saarimäki, Jonas Hugosson, Teuvo L Tammela, et al.
Plos One|April 22, 2016
Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening TrialThea Veitonmäki, Teemu J Murtola, Kirsi Talala, et al.
Cancer Causes & Control : CCC|July 27, 2021
Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate CancerS D Walter, Jiarui Hu, Kirsi Talala, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2018
Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register dataNeill Booth, Pekka Rissanen, Teuvo L J Tammela, et al.
Pageof 7